Archives
Reasons Why You Should Get Genetic Testing
Among the advantages of genetic testing, it can confirm a diagnosis and help predict how a disease will progress, giving vital information for treatment.
2019 Lasting Impression Photo Contest Winners
Meet the winners of Quest’s Lasting Impression Photo Contest
Tags: Lasting Impression, Staying Active
Advancing Health, One Research Study at a Time
Mikey (left) is in a clinical trial for a DMD therapy. The medication could benefit his brother, Reid (right), and many other boys with DMD. MDA families can get involved…
Tags: Clinical Trials, Featured Content, MOVR, Research
MDA Awards More Than $1 Million in Venture Philanthropy Funding to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia
AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich’s ataxia (FA), was awarded MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio’s phase 2 clinical trial of a…
Tags: Clinical Trials, Gene Therapy, Grants
FDA Approves ITF Pharma’s Tiglutik via PEG Tube for the Treatment of ALS
On Dec. 13, the US Food and Drug Administration (FDA) approved expanded labeling for ITF Pharma’s Tiglutik to include administration via percutaneous endoscopic gastrostomy (PEG) tube for the treatment of…
Tags: Drug Approval, Research Advances
Mallinckrodt Pharmaceuticals Releases Statement to DMD Community Announcing Discontinuation of Clinical Trials Program for DMD
Yesterday, Mallinckrodt Pharmaceuticals released a statement to the Duchenne muscular dystrophy (DMD) community regarding its decision to discontinue its DMD clinical development program. The full statement follows. After careful consideration and despite…
Tags: Clinical Trials, Research
Amylyx Pharmaceuticals Announces Positive Results from Phase 2 Study of AMX0035 for Treatment of ALS
On Dec. 17, Amylyx Pharmaceuticals and the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital announced positive results from the phase 2 (CENTAUR) trial assessing treatment…
Solid Biosciences Releases Letter to DMD Community Announcing Update on IGNITE DMD Trial, Resolution of Serious Adverse Event
Today, Solid Biosciences released a letter to the Duchenne muscular dystrophy (DMD) community regarding updates on a serious adverse event (SAE) experienced by one child dosed last November and new biomarker data…
Santhera Pharmaceuticals Announces Publication of Positive Long-Term Results from Retrospective Study of Idebenone in DMD
On Nov. 19, Santhera Pharmaceuticals announced publication of long-term data from its SYROS study showing a reduction of decline in lung function in people with Duchenne muscular dystrophy (DMD) who were…
Wave Life Sciences Releases Letter to DMD Community Announcing Discontinuation of Clinical Trials Program for Therapies Amenable to Skipping Exons 51 and 53
Today, Wave Life Sciences released a letter to the Duchenne muscular dystrophy (DMD) community regarding its decision to discontinue its DMD clinical development program for suvodirsen, its therapy for patients amenable to…
Tags: Clinical Trials, Drug Development, Research